Hamburg (ots) - achtung! gewinnt bei den PR Report Awards 2017 die Auszeichnung für die beste ...
Avastin Label Updated Reflecting Confidence in Safety Profile
Basel, Switzerland (ots/PRNewswire) - - Contraindication for Patients With Untreated Brain Metastases Removed
- For non-US, UK and Austrian Media Only
The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin(R) (bevacizumab) in some patients whose primary cancer has spread to their brain (brain metastases). The label change is based on safety data which show that the risk of bleeding in patients with untreated brain metastases is similar for patients who receive Avastin and those who do not. The updated label supports Avastin's well established safety profile across various tumour types.
Brain metastases can bleed and potentially cause severe problems for patients, regardless of any treatment given. These metastases develop when cancer cells break away from primary tumours in other organs in the body and travel through the bloodstream to the brain. This occurs most often with lung cancer but can also occur in breast, skin (malignant melanoma), kidney, and colon cancers.
Avastin is approved for the treatment of the advanced stages of four of the most common cancers: colorectal cancer, breast cancer, lung cancer and renal cell cancer and has already helped more than 500,000 patients with cancer worldwide.
Commenting on the updated label, Professor Jean-Charles Soria from Institut Gustave Roussy, Villejuif, France, said: "The fact that the change to the label is based on a comprehensive safety database gives added confidence in use of this major cancer treatment for patients with many different types of cancer."
The EMEA made their decision following review of a number of analyses from clinical trials, as well as a safety database generated through use of Avastin for more than a decade. Data were reviewed from randomised, controlled and open label clinical studies and the company's safety database. This includes data from the USA where Avastin has never been contraindicated for use in patients with brain metastases.
Avastin is an innovative medicine that limits the growth of blood vessels feeding cancerous tissues with oxygen and nutrients. It works by blocking angiogenesis; an important and unique therapeutic target common to most cancers and which is crucial to cancer growth. There are more than 450 clinical trials underway to investigate the use of Avastin in over 30 tumour types.
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at http://www.roche.com.
All trademarks used or mentioned in this release are legally protected.
To access video clips about Avastin in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com.
Tina Phelan, Galliard Healthcare, +44-207-663-2254,